International Journal of Clinical Research
International Journal of Clinical Research. 2025; 9: (5) ; 10.12208/j.ijcr.20250244 .
总浏览量: 96
1 大理大学临床医学院 云南大理
2 大理大学第二附属医院(云南省第三人民医院)消化内科 云南昆明
*通讯作者: 郑盛,单位: 大理大学第二附属医院(云南省第三人民医院)消化内科 云南昆明;
目的 探索胃蛋白酶原I(PGI)、胃蛋白酶原II(PGII)、PGI/PGII(PGR)、胃泌素17(G-17)联合检测对Hp相关慢性非萎缩性胃炎的应用价值。方法 选取2024年1月至2024年11月大理大学第二附属医院确诊为慢性非萎缩性胃炎的患者80例,其中合并Hp阳性患者40例为研究组,Hp阴性患者40例为对照组。收集血清学标本,检测PGI、PGII、G-17浓度,并计算PGR。比较2组受试者上述4项指标差异性,用受试者工作曲线评估 PGI、PGII、PGR、G-17在Hp相关慢性非萎缩性胃炎的临床应用价值。结果 Hp阳性慢性非萎缩性胃炎患者PGI(187.99μg/L VS 122.29μg/L,P<0.05)、PGII(9.52μg/L VS 7.32μg/L,P<0.05)、G-17(5.59 pmol/L VS 3.47 pmol/L,P<0.05)高于Hp阴性慢性非萎缩性胃炎患者;PGI、PGII、G-17单独检测诊断Hp感染慢性非萎缩性胃炎的AUC值分别为0.754、0.680、0.649,联合检测AUC值为0.762,联合检测诊断效能较高。结论 血清PGI、PGII、G-17对鉴别慢性非萎缩性胃炎是否合并Hp感染更具临床价值。
Objective To explore the application value of combined detection of pepsinogen I (PGI), pepsinogen II (PGII), PGI/PGII (PGR) and gastrin 17 (G-17) in Hp-related chronic non-atrophic gastritis. Methods A total of 80 patients diagnosed with chronic non-atrophic gastritis from the Third People's Hospital of Yunnan Province from January 2024 to November 2024 were selected, including 40 Hp-positive patients as the study group and 40 Hp-negative patients as the control group. Serological specimens were collected, PGI, PGII, G-17 concentrations were detected, and PGR was calculated. The differences of the above 4 indexes between the two groups were compared, and the clinical application value of PGI, PGII, PGR and G-17 in Hp-related chronic non-atrophic gastritis was evaluated by subject work curve. Results In Hp-positive patients with chronic non-atrophic gastritis, PGI (187.99μg/L VS 122.29μg/L,P<0.05),PGII (9.52μg/L VS 7.32μg/L,P<0.05), PG-17 (5.59 pmol/L VS 3.47 pmol/L,P<0.05), higher than Hp-negative chronic non-atrophic gastritis;The AUC values of PGI, PGII and G-17 were 0.754, 0.680 and 0.649, respectively, and the AUC values of combined detection were 0.762, indicating that the combined detection had high diagnostic efficiency. Conclusion Serum PGI, PGII and G-17 are more valuable in differentiating chronic non-atrophic gastritis with Hp infection.
[1] 张新萍,姜璐,郑琳洁,等.基于网络药理学及分子对接技术探讨快胃片治疗慢性非萎缩性胃炎的机制[J].现代药物与临床,2024,39(10):2502-2509. 2.
[2] 张小艳,任佳佳,赵恒芳,等.IL-10在H.pylori相关性胃炎组织中的表达及与COX-iNOS的相关性[J].现代肿瘤医学, 2019, 27(02):269-274.
[3] 陆瑛,杨晓军.血清PG、G-17、IL-10在不同菌型Hp感染慢性非萎缩性胃炎中的表达及对预后评估的价值分析[J].中国现代药物应用,2023,17(18):34-38.
[4] Yue P, Zhong J, Huang J, Lan Z, Zhong S. The efficacy and safety of Xiangsha Liujunzi decoction in the treatment of chronic non-atrophic gastritis: A protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2021;100(4):e24504.
[5] Kuligowski J, Sanjuan-Herráez D, Vázquez-Sánchez MA, et al. Metabolomic Analysis of Gastric Cancer Progression within the Correa's Cascade Using Ultraperformance Liquid Chromatography-Mass Spectrometry. J Proteome Res. 2016;15(8):2729-2738.
[6] Trivanovic D, Plestina S, Honovic L, Dobrila-Dintinjana R, Vlasic Tanaskovic J, Vrbanec D. Gastric cancer detection using the serum pepsinogen test method. Tumori. 2022;108(4):386-391.
[7] Di Mario F, Crafa P, Barchi A, et al. Pepsinogen II in gastritis and Helicobacter pylori infection. Helicobacter. 2022;27(2):e12872.
[8] Nasier-Hussain M, Samanje JN, Mokhtari K, et al. Serum levels of oxidative stress, IL-8, and pepsinogen I/II ratio in Helicobacter pylori and gastric cancer patients: potential diagnostic biomarkers. BMC Gastroenterol. 2025;25(1):2. Published 2025 Jan 2.
[9] 高晓双,李娜.胃食管反流病患者血清胃泌素17、胃蛋白酶原和多巴胺的水平及临床意义[J].食管疾病,2024,6(01): 60-64.
[10] Li Y, Liu X, Luo Y, Wang Q. Pepsinogen ratio and brachial-ankle pulse wave velocity: a cross-sectional study on their interrelationship in atherosclerosis. BMC Cardiovasc Disord. 2023;23(1):572. Published 2023 Nov 21.
[11] 韩强,程艳丽.幽门螺杆菌感染根除治疗研究新进展[J].中国研究型医院,2023,10(03):51-55.
[12] Zhou X, Zhu H, Zhu C, et al. Helicobacter pylori Infection and Serum Pepsinogen Level With the Risk of Gastric Precancerous Conditions: A Cross-sectional Study of High-risk Gastric Cancer Population in China. J Clin Gastroenterol. 2021;55(9):778-784.
[13] 袁林,丁松泽,张延瑞,等.不同类型幽门螺杆菌在慢性胃病中感染情况及对胃泌素-17和胃蛋白酶原的影响[J].中华实用诊断与治疗杂志,2020,34(04):382-385.
[14] akayama T, Suzuki H, Okada K, et al. Prediction of true Helicobacter pylori-uninfected status using a combination of age, serum antibody and pepsinogen: Logistic regression analysis. PLoS One. 2020;15(10):e0240040. Published 2020 Oct 1.
[15] Kim DB, Jo IH, Paik CN, Kim YJ, Lee JM. Serum Pepsinogen and Gastrin Levels: Reliable Markers to Predict Small Intestinal Bacterial Overgrowth. Turk J Gastroenterol. 2022;33(3):213-220.
[16] 李云鹏,张园,丁永年.胃泌素与胃息肉相关性的研究进展[J].中国医学创新,2024,21(36):176-179.
[17] Parhusip DH, Siregar GA, Dairi LB. The Difference of Serum Gastrin-17 Level Based on Gastritis Severity and Helicobacter Pylori Infection. Open Access Maced J Med Sci. 2019;7(8):1266-1269. Published 2019 Apr 29.
[18] 黄更新,陈玲红,连丽凤,等.幽门螺杆菌不同菌型感染对慢性非萎缩性胃炎血清PG、G-17及IL-10表达的影响[J].中外医疗,2021,40(31):80-83.
[19] 吴琦玮,高杨,李艳辉,等.胃泌素、胃蛋白酶原水平与幽门螺杆菌所致胃黏膜病变的相关性[J].中国临床医生杂志, 2024, 52(12):1433-1435.
[20] 段友红.胃蛋白酶原及胃泌素-17检测在胃肠疾病诊断中的作用[J].蚌埠医学院学报,2018,43(08):1064-1066.